| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 4 |
| 1 | DOXORUBICIN | 4 |
| 2 | FLUOROURACIL | 4 |
| 3 | FLUOROURACIL CREAM, 0.5% | 4 |
| 4 | NIRSEVIMAB | 3 |
| 5 | ACYCLOVIR | 1 |
| 6 | ALBUTEROL | 1 |
| 7 | ALBUTEROL SULFATE | 1 |
| 8 | AMLODIPINE | 1 |
| 9 | ANTACID | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIRSEVIMAB | 3 | 0.0017 |
| 1 | DEFLAZACORT | 1 | 0.0004 |
| 2 | DRONABINOL | 1 | 0.0001 |
| 3 | AXICABTAGENE CILOLEUCEL | 1 | 0.0001 |
| 4 | FLUOROURACIL CREAM, 0.5% | 4 | 0.0001 |
| 5 | FLUOROURACIL | 4 | 0.0001 |
| 6 | CISPLATIN | 4 | 0.0001 |
| 7 | DOXORUBICIN | 4 | 0.0000 |
| 8 | DOXORUBICIN HYDROCHLORIDE | 1 | 0.0000 |
| 9 | LOPERAMIDE HYDROCHLORIDE | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] | 3 | 0.0017 |
| 1 | Cannabinoid [EPC] | 1 | 0.0001 |
| 2 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |
| 3 | BCL-2 Inhibitor [EPC] | 1 | 0.0000 |
| 4 | Platinum-based Drug [EPC] | 4 | 0.0000 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 4 | 0.0000 |
| 6 | Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 8 | Serotonin-3 Receptor Antagonist [EPC] | 1 | 0.0000 |
| 9 | Opioid Agonist [EPC] | 1 | 0.0000 |